ICU内疑似上消化道出血患者胃镜治疗获益的预测:SUGIBI评分研究
本研究为回顾性研究,在ICU中纳入255例非因消化道出血入院的疑似上消化道出血(SUGIB)患者,分析床旁胃镜(EGD)需行止血治疗的相关因素并建立SUGIBI评分,随后在回顾性多中心队列中验证。结果显示仅12.9%患者接受了内镜下止血治疗;SUGIBI评分<4分对止血治疗的阴性预测值为95%(91-99),AUC为0.81(0.75-0.91)(p<0.0001);多中心验证队列AUC为0.75(0.66-0.85)(p<0.0001),评分<4分阴性预测值为95%(92-97)。作者认为床旁急诊胃镜对ICU疑似上消化道出血患者的治疗获益仅限于少数患者,SUGIBI评分有助于临床医生分层评估胃镜治疗获益概率。
要点
- SUGIBI评分<4分对ICU疑似上消化道出血患者胃镜下止血治疗的阴性预测值为95%(91-99),推导队列AUC为0.81(0.75-0.91)(p<0.0001)。
- 多中心验证队列中SUGIBI评分<4分的阴性预测值为95%(92-97),AUC为0.75(0.66-0.85)(p<0.0001)。
- 255例ICU疑似上消化道出血患者中仅12.9%在胃镜下接受止血治疗,胃镜正常者占24.7%。
- 胃镜主要指征为贫血(79%)、黑便(19%)、休克(14%)和呕血(13%)。
- 作者认为床旁急诊胃镜对ICU疑似上消化道出血患者的治疗获益仅限于少数患者,SUGIBI评分有助于分层评估胃镜治疗获益概率。
适用人群与场景
- ICU住院期间出现疑似上消化道出血(SUGIB)、非因消化道出血原发入院的成人患者,接受床旁胃镜检查。
诊断标准与关键阈值
- SUGIBI评分<4分:对胃镜下止血治疗的阴性预测值为95%(91-99),推导队列AUC为0.81(0.75-0.91)(p<0.0001)。
- 多中心验证队列中SUGIBI评分<4分:阴性预测值为95%(92-97),AUC为0.75(0.66-0.85)(p<0.0001)。
研究设计与关键结果
- 研究类型:回顾性研究,在ICU中分析255例非因消化道出血入院、因SUGIB行床旁胃镜的患者,建立SUGIBI评分,并在回顾性多中心队列中验证。
- 胃镜指征:贫血79%、黑便19%、休克14%、呕血13%。
- 胃镜结果:正常24.7%,溃疡23.1%,食管炎18.8%,胃炎12.5%;仅12.9%接受内镜下止血治疗。
- 推导队列:SUGIBI评分<4分对止血治疗的阴性预测值为95%(91-99),AUC为0.81(0.75-0.91)(p<0.0001)。
- 验证队列:SUGIBI评分<4分对止血治疗的阴性预测值为95%(92-97),AUC为0.75(0.66-0.85)(p<0.0001)。
证据类型、等级与局限
- 证据类型:回顾性研究(推导队列)及回顾性多中心队列验证。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为床旁急诊胃镜对ICU疑似上消化道出血患者的治疗获益仅限于少数患者。
- 作者认为SUGIBI评分应有助于临床医生分层评估胃镜治疗获益的概率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Suspected upper gastrointestinal bleeding (SUGIB) is a common issue during ICU stay. In the absence of specific guidelines on the indication and timing of esophagogastroduodenoscopy (EGD), there is substantial variability in EGD indication depending on accessibility and clinical presentation. This study aimed to investigate factors associated with the need for per-EGD hemostatic therapy and to create a score predicting therapeutic benefit of emergency bedside EGD in ICU patients with SUGIB.
METHODS: We conducted a retrospective study in our ICU to identify factors associated with the need for hemostatic procedure during EGD performed for SUGIB. From this observational cohort, we derived a score predicting the need for hemostasis during EGD, the SUGIBI score. This score was subsequently validated in a retrospective multicenter cohort.
RESULTS: Two hundred fifty-five patients not primarily admitted for GI bleeding who underwent a bedside EGD for SUGIB during their ICU stay were analyzed. The preeminent EGD indication were anemia (79%), melena (19%), shock (14%), and hematemesis (13%). EGD was normal in 24.7% of cases, while primary lesions reported were ulcers (23.1%), esophagitis (18.8%), and gastritis (12.5%). Only 12.9% of patients underwent hemostatic endotherapy during EGD. A SUGIBI score < 4 had a negative predictive value of 95% (91-99) for hemostatic endotherapy [AUC of 0.81; 0.75-0.91 (p < 0.0001)]. The SUGIBI score for predicting the need for an EGD-guided hemostatic procedure was next validated in a multicenter cohort with an AUC of 0.75 (0.66-0.85) (p < 0.0001), a score < 4 having a negative predictive value of 95% (92-97).
CONCLUSIONS: Our study shows that the therapeutic usefulness of bedside emergency EGD for SUGIB in critically ill patients is limited to a minority of patients. The SUGIBI score should help clinicians stratify the probability of a therapeutic EGD.
参考来源
- Penaud V, Vieille T, Urbina T, et al. Prediction of esophagogastroduodenoscopy therapeutic usefulness for in-ICU suspected upper gastrointestinal bleeding: the SUGIBI score study. Ann Intensive Care. 2024. PMID: 38361004. doi:10.1186/s13613-024-01250-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。